Evidence map›Paper›PMID 36814293›Full record

ArticleJournal of translational medicine2023

Identification and validation of a novel prognostic signature based on mitochondria and oxidative stress related genes for glioblastoma.

Shiao Tong, Minqi Xia, Yang Xu, Qian Sun, Liguo Ye, Fanen Yuan, Yixuan Wang, Jiayang Cai, Zhang Ye, Daofeng Tian

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Identification ofBiomedicines · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Shiao Tong *Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Minqi Xia *Department of Endocrinology & Metabolism, Renmin Hospital of Wuhan University, Wuhan, China.
Yang XuDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Qian SunDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Liguo YeDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Fanen YuanDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Yixuan WangDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Jiayang CaiDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Zhang YeDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Daofeng TianDepartment of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China. tiandaofeng@hotmail.com.ORCID 0000-0002-2023-0060
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMitochondria represent a major source of reactive oxygen species (ROS) in cells, and the direct increase in ROS content is the primary cause of oxidative stress, which plays an important role in tumor proliferation, invasion, angiogenesis, and treatment. However, the relationship between mitochondrial oxidative stress-related genes and glioblastoma (GBM) remains unclear. This study aimed to investigate the value of mitochondria and oxidative stress-related genes in the prognosis and therapeutic targets of GBM.

methodsWe retrieved mitochondria and oxidative stress-related genes from several public databases. The LASSO regression and Cox analyses were utilized to build a risk model and the ROC curve was used to assess its performance. Then, we analyzed the correlation between the model and immunity and mutation. Furthermore, CCK8 and EdU assays were utilized to verify the proliferative capacity of GBM cells and flow cytometry was used to analyze apoptosis rates. Finally, the JC-1 assay and ATP levels were utilized to detect mitochondrial function, and the intracellular ROS levels were determined using MitoSOX and BODIPY 581/591 C11.

results5 mitochondrial oxidative stress-related genes (CTSL, TXNRD2, NUDT1, STOX1, CYP2E1) were screened by differential expression analysis and Cox analysis and incorporated in a risk model which yielded a strong prediction accuracy (AUC value = 0.967). Furthermore, this model was strongly related to immune cell infiltration and mutation status and could identify potential targeted therapeutic drugs for GBM. Finally, we selected NUDT1 for further validation in vitro. The results showed that NUDT1 was elevated in GBM, and knockdown of NUDT1 inhibited the proliferation and induced apoptosis of GBM cells, while knockdown of NUDT1 damaged mitochondrial homeostasis and induced oxidative stress in GBM cells.

conclusionOur study was the first to propose a prognostic model of mitochondria and oxidative stress-related genes, which provided potential therapeutic strategies for GBM patients.

Indexed as

Genes, MitochondrialGlioblastomaOxidative StressHumansPrognosisReactive Oxygen SpeciesReactive Oxygen SpeciesGlioblastomaMitochondriaOxidative stressPrognosisRisk score

Identifiers

PMID36814293
PMCPMC9948483
OpenAlexW4321482784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.